EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum

Per Ljungman iD, Roy F Chemaly, Fareed Khawaya, Sophie Alain, Robin Avery, Cyrus Badshah, Michael Boeckh, Martha Fournier, Aimee Hodowanec, Takashi Komatsu, Ajit P Limaye, Oriol Manuel und 9 weitere

Clinical Infectious Diseases · 26.09.2024 · 79 (3) · 787-794

DOI: 10.1093/cid/ciae321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 23.07.2024. Verfasst von Per Ljungman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Cen…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Antiviral Agents, Cytomegalovirus, Transplant Recipients. Die Arbeit wurde bisher 206-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Forum, AiCuris, AlloVir.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2017. Since then, there have been major developments, including registration of new antiviral agents. Therefore, the Transplant Associated Virus Infections Forum, which consists of scientists, clinicians, regulators, and industry representatives, has produced an updated version of these definitions that incorporates recent knowledge with the aim of supporting clinical research and drug development. This also includes an update regarding the definition of resistant and refractory CMV infections previously published in 2019. As the field evolves, the need for updates of these definitions is clear, and collaborative efforts among clinicians, scientists, regulators, and industry representatives can provide a platform for this work.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsAntiviral AgentsCytomegalovirusTransplant RecipientsClinical Trials as TopicHumansDrug Resistance, ViralOrgan Transplantation

Stichwörter der Autor:innen

CMVclinical trialsdisease definitionsorgan transplantationstem cell transplantation

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
  • Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Laboratoire de Bactériologie-Virologie-Hygiène, French National Reference Center for Herpesviruses, CHU Limoges, Limoges, France.
  • Division of Infectious Diseases, Johns Hopkins, Baltimore, Maryland, USA.
  • Merck & Co, Inc., Rahway, New Jersey, USA.

ORCID-Profile: Per Ljungman, Raymund R Razonable

Förderung

  • Forum
  • AiCuris
  • AlloVir
  • Evrys Bio
  • HHV-6 Foundation
  • Merck
  • Takeda
  • Symbio

Zitieren

APA

Ljungman, P., Chemaly, R. F., Khawaya, F., Alain, S., Avery, R., Badshah, C., Boeckh, M., Fournier, M., Hodowanec, A., Komatsu, T., Limaye, A. P., Manuel, O., Natori, Y., Navarro, D., Pikis, A., Razonable, R. R., Westman, G., Miller, V., Griffiths, P. D., …, & CMV Definitions Working Group of the Transplant Associated Virus Infections Forum (2024). Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clinical Infectious Diseases, 79(3), 787-794. https://doi.org/10.1093/cid/ciae321

Vancouver

Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, et al. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clinical Infectious Diseases. 2024;79(3):787-794. doi:10.1093/cid/ciae321

BibTeX
@article{Ljungman2024,
  author = {Ljungman, Per and Chemaly, Roy F and Khawaya, Fareed and Alain, Sophie and Avery, Robin and Badshah, Cyrus and Boeckh, Michael and Fournier, Martha and Hodowanec, Aimee and Komatsu, Takashi and Limaye, Ajit P and Manuel, Oriol and Natori, Yoichiro and Navarro, David and Pikis, Andreas and Razonable, Raymund R and Westman, Gabriel and Miller, Veronica and Griffiths, Paul D and Kotton, Camille N and CMV Definitions Working Group of the Transplant Associated Virus Infections Forum, CMV Definitions Working Group of the Transplant Associated Virus Infections Forum},
  title = {Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {79},
  number = {3},
  pages = {787--794},
  doi = {10.1093/cid/ciae321}
}
Kostenlos starten →